Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Targeting Blood Vessel Stiffness to Protect Kidney Function

Neeraj Dhaun and David J. Webb
CJASN December 2015, 10 (12) 2107-2109; DOI: https://doi.org/10.2215/CJN.11331015
Neeraj Dhaun
*University/British Heart Foundation Centre of Research Excellence, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, United Kingdom; and
†Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Webb
*University/British Heart Foundation Centre of Research Excellence, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • arterial stiffness
  • glomerular filtration rate
  • renal function decline
  • chronic kidney disease

Cardiovascular disease (CVD) commonly accompanies CKD. Although many patients with CKD have other risk factors for CVD (for example, diabetes or smoking) and part of the increased risk is attributable to these, studies show that CKD itself is a major independent risk factor (1). In one large Canadian study, patients ages 30 years old with CKD stage 3B (eGFR=30–44 ml/min per 1.73 m2) or 4 (15–29 ml/min per 1.73 m2) had reductions in life expectancy of around 17 or 25 years, respectively, compared with individuals with normal kidney function (2). In patients on dialysis, mortality from CVD is >10–20 times that of the general population; for a patient <45 years old, this rises to 100 times (3). Such figures led the US National Kidney Foundation Task Force on CVD in Chronic Renal Disease to recognize in 1998 that patients with chronic renal disease should be considered in the highest risk group for subsequent cardiovascular events (4).

Both epidemiologic and clinical data show that damage to large arteries contributes to the increased cardiovascular risk observed in CKD (5). Atherosclerosis is the most frequent cause of arterial damage (6), but the medial calcification seen in CKD also leads to arterial stiffening. This stiffening not only causes an elevation in central systolic BP, increasing left ventricular workload with the gradual development of left ventricular hypertrophy, but also, causes a fall in diastolic BP, impairing coronary blood flow. Arterial calcification and stiffness are important independent predictors of all-cause and cardiovascular mortality in patients with CKD (7).

Much of the early data in studies of arterial stiffness concentrated on patients with ESRD. Increased arterial stiffness (as measured by well validated indices of stiffness: augmentation index and pulse wave velocity [PWV] [8]) is a strong independent predictor of mortality in patients with ESRD (9). This reflects the elevated central pressure, increased cardiac workload, impaired coronary perfusion, and development of left ventricular hypertrophy associated with increased stiffness. Moreover, a therapeutic trial in patients with ESRD by Guerin et al. (10) has shown that, after long–term BP reduction, cardiovascular survival is observed mainly in those patients showing both adequate BP and PWV reduction (10). Patients with appropriate BP reduction but who maintained elevated PWV did not survive, an observation that underlines the critical deleterious influence of increased arterial stiffness on mortality in ESRD. Epidemiologic studies tell us that there is increased cardiovascular risk early on in CKD, and this risk increases as eGFR declines (11). In parallel with this, there is also an increase in PWV related to progression through the CKD stages (12,13). However, studies examining whether measures of arterial stiffness might predict future development or decline of CKD have been conflicting (14–16).

In this issue of the Clinical Journal of the American Society of Nephrology, Sedaghat et al. (17) present interesting and novel data from a large population–based study in Rotterdam backed up by a meta-analysis of other studies. Sedaghat et al. (17) measured pulse pressure (PP), carotid stiffness, and carotid-femoral PWV in approximately 3700 subjects and then, assessed annual decline in eGFR over a median follow-up period of 11 years. Furthermore, on the basis of ten single-nucleotide polymorphisms associated with PP and nine single-nucleotide polymorphisms associated with PWV, Sedaghat et al. (17) calculated a genetic risk score for these measures for all participants. After correcting for confounding factors (including BP), both PP and carotid stiffness predicted incident CKD and annual eGFR decline, whereas perhaps surprisingly, PWV did not. Interestingly, when Sedaghat et al. (17) combined their data with those of three other population–based studies using similar methodologies (a total of >10,000 subjects with follow-up periods of 5–10 years), they found that each SD higher PP and PWV was associated with 16% and 8% increased risk of incident CKD, respectively. Whereas genetic risk scoring for PP was associated with eGFR decline, genetic scoring for PWV was not.

Clearly, these data raise the intriguing possibility that targeting PWV from a therapeutic perspective (unstiffening the large vessels) might slow the progression of existing CKD and more importantly, perhaps, from an economic and public health perspective, prevent incident CKD. We already know that lowering BP will reduce PWV (8). However, there are few clinical trials to date showing that lowering of PWV with medical treatment results in different cardiovascular or renal outcomes (10,18) independent of BP. However, the importance of such studies is underscored by epidemiologic data that suggest that PWV is an independent risk factor for CVD morbidity and mortality (9,19,20). Karalliedde et al. (21) showed a BP-independent reduction in PWV with valsartan compared with amlodipine in patients with type 2 diabetes and proteinuria, and the same has been shown after brief administration of an endothelin antagonist to nondiabetic patients with CKD who are proteinuric (22). There also exists other mechanisms to reduce arterial stiffness that do not involve BP lowering; these include the use of phosphate binders, such as sevelamer (23).

One might ask about the generalizability of the results of this study (17). The population studied had a mean age of 65 years old, and 60% were women. No information on race is given, but it is likely to be predominantly white. BP was normal, and there was an approximately 8% prevalence of diabetes and clinically apparent coronary artery disease at the start of the study. Baseline eGFR was approximately 80 ml/min per 1.73 m2. Over the 11-year follow-up period, there was an approximately 16% incidence of new CKD. These data are all consistent with a representative Western population, although the mean PWV of 12.2 m/s is higher than one might expect for such a population (24), and the reasons for this are not immediately clear. Furthermore, no data are available on proteinuria, central BP components, or incident CVD, all of which are linked to arterial stiffness and would be of interest.

A recent paper by London et al. (25) has added to the field by suggesting that, in addition to assessing aortic stiffness in patients with renal disease, aortic geometry may also provide valuable prognostic information. In patients with ESRD established on hemodialysis, London et al. (25) found that, such as for PWV, aortic bifurcation diameter (and aortic taper—defined as ascending aorta-to-aorta bifurcation diameters ratio) independently predicted all-cause and cardiovascular mortality. Because those with earlier stages of CKD are more likely to die from CVD than reach ESRD, they should certainly be the focus of future studies. Nevertheless, it is important to remember that patients with ESRD, especially those on hemodialysis, are at the greatest risk of CVD. Given that they attend medical facilities three times per week, they represent a captive audience for future clinical trials in a group where few therapeutic interventions have been shown to improve outcome. This group has marked arterial stiffness, and there is now an urgent need for trials addressing reversal of arterial stiffness and left ventricular mass alongside aortic geometry and endothelial function.

Disclosures

None.

Acknowledgments

N.D. is supported by British Heart Foundation Intermediate Clinical Research Fellowship (grant no.: FS/13/30/29994).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Arterial Stiffness and Decline in Kidney Function,” on pages 2190–2197.

  • Copyright © 2015 by the American Society of Nephrology

References

  1. ↵
    1. Go AS,
    2. Chertow GM,
    3. Fan D,
    4. McCulloch CE,
    5. Hsu CY
    : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
    OpenUrlCrossRefPubMed
  2. ↵
    1. Turin TC,
    2. Tonelli M,
    3. Manns BJ,
    4. Ravani P,
    5. Ahmed SB,
    6. Hemmelgarn BR
    : Chronic kidney disease and life expectancy. Nephrol Dial Transplant 27: 3182–3186, 2012
    OpenUrlCrossRefPubMed
  3. ↵
    1. Foley RN,
    2. Parfrey PS,
    3. Sarnak MJ
    : Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112–S119, 1998
    OpenUrlCrossRefPubMed
  4. ↵
    1. Levey AS,
    2. Beto JA,
    3. Coronado BE,
    4. Eknoyan G,
    5. Foley RN,
    6. Kasiske BL,
    7. Klag MJ,
    8. Mailloux LU,
    9. Manske CL,
    10. Meyer KB,
    11. Parfrey PS,
    12. Pfeffer MA,
    13. Wenger NK,
    14. Wilson PW,
    15. Wright JT Jr..
    : Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32: 853–906, 1998
    OpenUrlCrossRefPubMed
  5. ↵
    US Renal Data System: USRDS 2004 annual data report. Am J Kidney Dis 45: 8–280, 2005
    OpenUrlCrossRef
  6. ↵
    1. Lindner A,
    2. Charra B,
    3. Sherrard DJ,
    4. Scribner BH
    : Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697–701, 1974
    OpenUrlCrossRefPubMed
  7. ↵
    1. Blacher J,
    2. Guerin AP,
    3. Pannier B,
    4. Marchais SJ,
    5. London GM
    : Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938–942, 2001
    OpenUrlCrossRefPubMed
  8. ↵
    1. Oliver JJ,
    2. Webb DJ
    : Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler Thromb Vasc Biol 23: 554–566, 2003
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Blacher J,
    2. Guerin AP,
    3. Pannier B,
    4. Marchais SJ,
    5. Safar ME,
    6. London GM
    : Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434–2439, 1999
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Guerin AP,
    2. Blacher J,
    3. Pannier B,
    4. Marchais SJ,
    5. Safar ME,
    6. London GM
    : Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987–992, 2001
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Gansevoort RT,
    2. Correa-Rotter R,
    3. Hemmelgarn BR,
    4. Jafar TH,
    5. Heerspink HJ,
    6. Mann JF,
    7. Matsushita K,
    8. Wen CP
    : Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382: 339–352, 2013
    OpenUrlCrossRefPubMed
  12. ↵
    1. Wang MC,
    2. Tsai WC,
    3. Chen JY,
    4. Huang JJ
    : Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45: 494–501, 2005
    OpenUrlCrossRefPubMed
  13. ↵
    1. Lilitkarntakul P,
    2. Dhaun N,
    3. Melville V,
    4. Blackwell S,
    5. Talwar DK,
    6. Liebman B,
    7. Asai T,
    8. Pollock J,
    9. Goddard J,
    10. Webb DJ
    : Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 216: 217–225, 2011
    OpenUrlCrossRefPubMed
  14. ↵
    1. Briet M,
    2. Collin C,
    3. Karras A,
    4. Laurent S,
    5. Bozec E,
    6. Jacquot C,
    7. Stengel B,
    8. Houillier P,
    9. Froissart M,
    10. Boutouyrie P
    ; Nephrotest Study Group: Arterial remodeling associates with CKD progression. J Am Soc Nephrol 22: 967–974, 2011
    OpenUrlAbstract/FREE Full Text
    1. Ford ML,
    2. Tomlinson LA,
    3. Chapman TP,
    4. Rajkumar C,
    5. Holt SG
    : Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 55: 1110–1115, 2010
    OpenUrlCrossRef
  15. ↵
    1. Madero M,
    2. Peralta C,
    3. Katz R,
    4. Canada R,
    5. Fried L,
    6. Najjar S,
    7. Shlipak M,
    8. Simonsick E,
    9. Lakatta E,
    10. Patel K,
    11. Rifkin D,
    12. Hawkins M,
    13. Newman A,
    14. Sarnak M
    ; Health ABC Study: Association of arterial rigidity with incident kidney disease and kidney function decline: The Health ABC study. Clin J Am Soc Nephrol 8: 424–433, 2013
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sedaghat S,
    2. Mattace-Raso FUS,
    3. Hoorn EJ,
    4. Uitterlinden AG,
    5. Hofman A,
    6. Ikram MA,
    7. Franco OH,
    8. Dehghan A
    : Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol 10: 2190–2197, 2015
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Williams B,
    2. Lacy PS,
    3. Thom SM,
    4. Cruickshank K,
    5. Stanton A,
    6. Collier D,
    7. Hughes AD,
    8. Thurston H,
    9. O’Rourke M
    ; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113: 1213–1225, 2006
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Laurent S,
    2. Boutouyrie P,
    3. Asmar R,
    4. Gautier I,
    5. Laloux B,
    6. Guize L,
    7. Ducimetiere P,
    8. Benetos A
    : Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37: 1236–1241, 2001
    OpenUrlCrossRefPubMed
  19. ↵
    1. Cruickshank K,
    2. Riste L,
    3. Anderson SG,
    4. Wright JS,
    5. Dunn G,
    6. Gosling RG
    : Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: An integrated index of vascular function? Circulation 106: 2085–2090, 2002
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Karalliedde J,
    2. Smith A,
    3. DeAngelis L,
    4. Mirenda V,
    5. Kandra A,
    6. Botha J,
    7. Ferber P,
    8. Viberti G
    : Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 51: 1617–1623, 2008
    OpenUrlCrossRef
  21. ↵
    1. Dhaun N,
    2. Macintyre IM,
    3. Melville V,
    4. Lilitkarntakul P,
    5. Johnston NR,
    6. Goddard J,
    7. Webb DJ
    : Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 54: 113–119, 2009
    OpenUrlCrossRef
  22. ↵
    1. Takenaka T,
    2. Suzuki H
    : New strategy to attenuate pulse wave velocity in haemodialysis patients. Nephrol Dial Transplant 20: 811–816, 2005
    OpenUrlCrossRefPubMed
  23. ↵
    1. Shinohara K,
    2. Shoji T,
    3. Tsujimoto Y,
    4. Kimoto E,
    5. Tahara H,
    6. Koyama H,
    7. Emoto M,
    8. Ishimura E,
    9. Miki T,
    10. Tabata T,
    11. Nishizawa Y
    : Arterial stiffness in predialysis patients with uremia. Kidney Int 65: 936–943, 2004
    OpenUrlCrossRefPubMed
  24. ↵
    1. London GM,
    2. Safar ME,
    3. Pannier B
    : Aortic aging in ESRD: Structural, hemodynamic, and mortality implications [published online ahead of print October 16, 2015]. J Am Soc Nephrol doi:ASN.2015060617
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 10 (12)
Clinical Journal of the American Society of Nephrology
Vol. 10, Issue 12
December 07, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Targeting Blood Vessel Stiffness to Protect Kidney Function
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Targeting Blood Vessel Stiffness to Protect Kidney Function
Neeraj Dhaun, David J. Webb
CJASN Dec 2015, 10 (12) 2107-2109; DOI: 10.2215/CJN.11331015

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Targeting Blood Vessel Stiffness to Protect Kidney Function
Neeraj Dhaun, David J. Webb
CJASN Dec 2015, 10 (12) 2107-2109; DOI: 10.2215/CJN.11331015
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Optimizing Utilization of Kidneys from Hepatitis C–Positive Kidney Donors
  • Mobile Health in Dialysis: The Best Engagement Medium Is the One that’s with Patients
  • Forever Starts Now
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Interstate Variation in Receipt of Nephrologist Care in US Patients Approaching ESRD: Race, Age, and State Characteristics
  • Arterial Stiffness and Decline in Kidney Function
  • PubMed
  • Google Scholar

Keywords

  • arterial stiffness
  • glomerular filtration rate
  • renal function decline
  • chronic kidney disease

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire